References
- Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z. (2001). The new pre-preclinical paradigm: Compound optimization in early and late phase drug discovery. Curr Top Med Chem, 1:353–66.
- Li P, Zhao L. (2007). Developing early formulations: Practice and perspective. Int J Pharm, 341:1–19.
- Jensen BS, Hertz M, Christophersen P, Madsen LS. (2002). The Ca2+-activated K+ channel of intermediate conductance: A possible target for immune suppression. Expert Opin Ther Targets, 6:623–36.
- Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, . (2000). Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem, 275:37137–49.
- Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, . (2003). The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J Clin Invest, 111:1703–13.
- Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. (2000). Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA, 97:8151–6.
- Deasy PB. (1984). Drugs and the pharmaceutical sciences: Microencapsulation and related drug processes. New York: Marcel Dekker.
- Dong W, Bodmeier R. (2006). Encapsulation of lipophilic drugs within enteric microparticles by a novel coacervation method. Int J Pharm, 326:128–38.
- Wahlstrom JL, Chiang P, Ghosh S, Warren CJ, Wene SP, Albin LA, . (2007). Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscal Res Lett, 2:291–6.
- Burgess DJ. (2005). Injectable dispersed systems: Formulation, processing, and performance. Boca Raton: Taylor & Francis.
- Barton AFM. (1983). CRC handbook of solubility parameters and other cohesion parameters. Florida: CRC Press Inc.
- Ashford M, Fell JT. (1994). Targeting drugs to the colon: Delivery systems for oral administration. J Drug Target, 2:241–57.
- Amorim MJ, Ferreira JP. (2001). Microparticles for delivering therapeutic peptides and proteins to the lumen of the small intestine. Eur J Pharm Biopharm, 52:39–44.
- Dong WY, Maincent P, Bodmeier R. (2007). In vitro and in vivo evaluation of carbamazepine-loaded enteric microparticles. Int J Pharm, 331:84–92.
- Wils P, Warnery A, Phung-Ba V, Legrain S, Scherman D. (1994). High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther, 269:654–8.